Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
pocket, reversible pan-KRAS inhibitor—Erasca says the orthogonal mechanisms give the company optionality across tumor types and future combinations. ERAS-0015 shows a reported potency advantage versus RMC-6236 (8–21× higher CYPA binding; ~1/10–1/5 the dose for comparable tumor regression), with early multiple responses at 8 mg, favorable PK attributes (higher oral bioavailability, longer half-life, linear PK AURORAS-1 (ERAS-0015) is enrolling rapidly with a planned first-half update on safety, PK and efficacy, BOREALIS-1 (ERAS-4001) has a second-half update and could move to 2027 dose-expansion/combination work, and Erasca aims to test pan-RAS plus anti-EGFR combinations in CRC in the second half to assess tolerability. Interested in Erasca, Inc.? Here are five stocks we like better. Erasca (NASDAQ:ERAS) executives outlined the company's strategy to target RAS-driven cancers and previewed upcoming clinical milestones during a fireside chat hosted by Oppenheimer oncology analy
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Tango rises after Q4 results, clinical pact with Erasca [Seeking Alpha]Seeking Alpha
- Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]Yahoo! Finance
- Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat [Yahoo! Finance]Yahoo! Finance
- Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and VopimetostatGlobeNewswire
- Assessing Erasca (ERAS) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 3/6/26 - Form 4
- 3/4/26 - Form 144
- 2/17/26 - Form 144
- ERAS's page on the SEC website